133 related articles for article (PubMed ID: 32535096)
41. Preparation, identification, activity prediction, and protective effects on IR-HepG2 cells of five novel DPP-IV inhibitory peptides from protein hydrolysate of skipjack tuna dark muscles.
Meng L; Song Y; Zheng B; Zhao Y; Hong B; Ma M; Wen Z; Miao W; Xu Y
Food Funct; 2023 Dec; 14(24):10991-11004. PubMed ID: 38019161
[TBL] [Abstract][Full Text] [Related]
42. Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities.
Hsu CY; Sulake RS; Huang PK; Shih HY; Sie HW; Lai YK; Chen C; Weng CF
Br J Pharmacol; 2015 Jan; 172(1):38-49. PubMed ID: 24977411
[TBL] [Abstract][Full Text] [Related]
43. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
44. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
45. Ginsenoside Rb2 promotes glucose metabolism and attenuates fat accumulation via AKT-dependent mechanisms.
Dai S; Hong Y; Xu J; Lin Y; Si Q; Gu X
Biomed Pharmacother; 2018 Apr; 100():93-100. PubMed ID: 29425748
[TBL] [Abstract][Full Text] [Related]
46. 20-HETE attenuates the response of glucose-stimulated insulin secretion through the AKT/GSK-3β/Glut2 pathway.
Zhang B; Lai G; Wu J; Sun R; Xu R; Yang X; Qi Y; Zhao Y
Endocrine; 2016 Nov; 54(2):371-382. PubMed ID: 27568038
[TBL] [Abstract][Full Text] [Related]
47. Sonchus oleraceus Linn extract enhanced glucose homeostasis through the AMPK/Akt/ GSK-3β signaling pathway in diabetic liver and HepG2 cell culture.
Chen L; Lin X; Fan X; Qian Y; Lv Q; Teng H
Food Chem Toxicol; 2020 Feb; 136():111072. PubMed ID: 31877369
[TBL] [Abstract][Full Text] [Related]
48. MiR-21 functions oppositely in proliferation and differentiation of neural stem/precursor cells via regulating AKT and GSK-3β.
Gao X; Li X; Qian C; Li F; Zhang Y; Dang L; Xiao X; Liu F; Li H; Zhang X
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):144-149. PubMed ID: 28971796
[TBL] [Abstract][Full Text] [Related]
49. Proteomic identification of 14-3-3zeta as an adapter for IGF-1 and Akt/GSK-3beta signaling and survival of renal mesangial cells.
Singh LP; Jiang Y; Cheng DW
Int J Biol Sci; 2006 Oct; 3(1):27-39. PubMed ID: 17200689
[TBL] [Abstract][Full Text] [Related]
50. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade.
Kim SJ; Nian C; McIntosh CH
J Biol Chem; 2007 Mar; 282(12):8557-67. PubMed ID: 17244606
[TBL] [Abstract][Full Text] [Related]
51. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
53. Shilianhua extract inhibits GSK-3beta and promotes glucose metabolism.
Yin J; Zuberi A; Gao Z; Liu D; Liu Z; Ye J
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1275-80. PubMed ID: 19351808
[TBL] [Abstract][Full Text] [Related]
54. Polydatin Improves Glucose and Lipid Metabolisms in Insulin-Resistant HepG2 Cells through the AMPK Pathway.
Hao J; Huang K; Chen C; Liang Y; Wang Y; Zhang X; Huang H
Biol Pharm Bull; 2018; 41(6):891-898. PubMed ID: 29863077
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
56. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
57. Dipeptidyl peptidase IV inhibitors and diabetes therapy.
McIntosh CH
Front Biosci; 2008 Jan; 13():1753-73. PubMed ID: 17981665
[TBL] [Abstract][Full Text] [Related]
58. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes.
Kim SJ; Nian C; McIntosh CH
J Biol Chem; 2007 Nov; 282(47):34139-47. PubMed ID: 17890220
[TBL] [Abstract][Full Text] [Related]
59. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
60. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
